LPC
DMAA

Lineage Point Capital’s Drugs Made In America Acquisition Corp DMAA Stock Holding History

Lineage Point Capital’s Portfolio DMAA Stock Details DMAA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$339K Hold
31,840
– – 0.07% 195
2026
Q1 		$334K Hold
31,840
– – 0.08% 152
2025
Q4 		$330K Buy
+31,840
New +$329K 0.13% 95

Other funds holding DMAA

KIM
Karpus Investment Management Pittsford, New York $3.48B AUM 10.49% 1-Year Est. Return
MSU
Mizuho Securities USA New York $6.2B AUM 35.46% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return
HCM
Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return
FTCM
First Trust Capital Management Chicago, Illinois $1.72B AUM 70.66% 1-Year Est. Return
HCM
Heights Capital Management San Francisco, California $433M AUM 8.59% 1-Year Est. Return
WCMNY
Westchester Capital Management (New York) Valhalla, New York $2.04B AUM 31.03% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $7.69B AUM 15.48% 1-Year Est. Return

Lineage Point Capital's DMAA Position: Q2 2026 in Review

Lineage Point Capital held its Drugs Made In America Acquisition Corp (DMAA) position steady in Q2 2026 at 31,840 shares worth $339K. The position accounts for 0.07% of the portfolio, ranked #195.

Lineage Point Capital first reported a position in DMAA in Q4 2025 and has held it in 3 quarters since. 23 funds tracked by Wall St. Rank hold DMAA as of Q2 2026.

  • Lineage Point Capital held 31,840 shares of Drugs Made In America Acquisition Corp worth $339K as of Q2 2026.
  • Lineage Point Capital left its Drugs Made In America Acquisition Corp share count unchanged in Q2 2026.
  • Drugs Made In America Acquisition Corp made up 0.07% of Lineage Point Capital's portfolio in Q2 2026, its #195 holding.
  • Lineage Point Capital first reported a position in Drugs Made In America Acquisition Corp in Q4 2025 and has held it in 3 quarters since.
  • 23 funds tracked by Wall St. Rank held Drugs Made In America Acquisition Corp as of Q2 2026.

Based on Lineage Point Capital's 13F filing for Q2 2026, filed 14 Aug 2026.